Stay updated on Safety and Efficacy of Aflibercept in AMD Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Aflibercept in AMD Clinical Trial page.

Latest updates to the Safety and Efficacy of Aflibercept in AMD Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check66 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check73 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study objectives and inclusion/exclusion criteria for a clinical trial on high-dose aflibercept for neovascular age-related macular degeneration, while adding new terminology and collaborators.SummaryDifference15%
Stay in the know with updates to Safety and Efficacy of Aflibercept in AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Aflibercept in AMD Clinical Trial page.